Resmetirom Update: Positioning the First Approved MASH Therapy
This narrative review consolidates the pivotal trial evidence, drug-interaction profile, and multi-guideline eligibility and monitoring recommendations that pharmacists need to safely implement resmetirom for fibrotic MASH.
Resmetirom is the first drug to reverse MASH and fibrosis.
Metabolic dysfunction-associated steatohepatitis (MASH) can progress to severe liver damage and lacks effective approved treatments. Resmetirom showed both resolution of MASH and improvement in fibrosis, leading to FDA and conditional EMA approvals. Clinicians now have a new therapeutic option for non-cirrhotic fibrotic MASH, with ongoing evaluation of its role alongside other treatments like semaglutide. Resmetirom offers a novel approach to reverse liver damage in metabolic dysfunction-associated steatohepatitis.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Van Kleef LA, Michel M, Alkhouri N, Brouwer WP, Schattenberg JM
Citation:Van Kleef LA, Michel M, Alkhouri N, et al. Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH). Drug design, development and therapy. 2026;20:559331. doi:10.2147/DDDT.S559331
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.